FDA accepts Cipher's response on acne treatment
 Wednesday, January 17, 2007

FDA accepts Cipher's response on acne treatment

Last Updated: 2007-01-17 9:00:38 -0400 (Reuters Health)

TORONTO (Reuters) - Cipher Pharmaceuticals Inc. said on Wednesday its response to its approvable letter for the acne treatment CIP-isotretinoin has been deemed complete by the U.S. Food and Drug Administration.

The company said the FDA has set April 27 as the action date for the approval of the treatment. ($1=$1.17 Canadian)



Go Back 		 
Schwartzapfel Partners
With over 150 years of combined experience and highly competent co-counsel throughout the country, we can serve all your legal needs. Schwartzapfel Partners protects the rights of those who aren't able to do so themselves.    Learn More



Gender: Male Female
In what state did the incident occur?
Schwartzapfel Truhowsky Marcus
       Sachs P.C. disclaimer.

Clear